Yu Shyr
-
May 28, 2020
Multinational consortium reports COVID-19 impact on cancer patients
People with cancer sickened by COVID-19 have a crude death rate of 13%, according to the largest series of data released thus far from a multinational perspective. The data on more than 900 patients, published May 28 in The Lancet and simultaneously presented at ASCO20 Virtual, also revealed cancer-specific factors associated with increased mortality. -
April 9, 2020
Research team awarded $9 million to study extracellular RNA in colorectal cancer
The NCI program project grant is supporting multiple projects that aim to define fundamental biological principles about extracellular RNA signaling and the development and aggressiveness of colorectal cancer, the second leading cause of cancer death in the United States. -
January 18, 2018
Lewis’ Discovery Lecture
Clinical trials expert Roger Lewis, MD, PhD, right, poses with Vanderbilt’s Yu Shyr, MD, following his recent Discovery Lecture. Lewis is chair of Emergency Medicine at Harbor-UCLA Medical Center in Los Angeles. -
July 20, 2017
Shyr named chair of Department of Biostatistics
Yu Shyr, Ph.D., Harold L. Moses Professor of Cancer Research and director of the Vanderbilt Center for Quantitative Sciences, has been named chair of Vanderbilt’s Department of Biostatistics. He will assume the post Sept. 1. -
November 25, 2016
Nine Vanderbilt faculty members elected AAAS fellows
Nine Vanderbilt University faculty members have been elected fellows of the American Association for the Advancement of Science this year. -
May 19, 2016
VICC investigators in spotlight at AACR conference
A top Vanderbilt-Ingram Cancer Center (VICC) investigator recently met with Vice President Joe Biden regarding the National Cancer Moonshot Initiative, a major national program to identify, fund and accelerate the most promising research leading to cancer cures. -
March 10, 2016
IOM study calls for better evidence for biomarker tests
Biomarker tests that help determine which patients may benefit from molecularly targeted therapies need better evidence and oversight to improve their effectiveness and availability, according to a study by the Institute of Medicine (IOM) of the National Academies of Sciences, Engineering, and Medicine.